The Center for Pharmaceutical Biotechnology and Nanomedicine is a recently organized research unit aiming to perform studies on the border between two fast growing scientific areas, Biotechnology and Nanomedicine. The missions of the Center include: 1. Intensive research in such areas as Nanomedicine (pharmaceutical nanocarriers with controllable properties for delivery and targeting of water-insoluble drugs, DNA, and diagnostic agents to various disease sites); Intracellular Drug Delivery (the use of cell penetrating peptides for delivery of drugs and DNA directly into the cell cytoplasm bypassing the endocytic pathway and increasing the efficiency of therapies); Experimental Cancer Immunotherapy (the research in the area of tumor-specific antibodies and the use of these antibodies for specific delivery of drugs and diagnostic agents to tumors); Combination Therapy of Cancer (research in the area of combined cancer therapy involving physical methods, such as radiofrequency ablation or thermal ablation, and traditional chemotherapy with the use on pharmaceutical nanocarriers); Novel Imaging Agents (engineering of new contrast agents for gamma-imaging and magnetic resonance imaging of various pathologies including cancer by using a combination of disease-specific monoclonal antibodies and pharmaceutical nanocarriers); 2. Training domestic and international students, postdoctoral fellows and visiting scientists for future academic, industrial and medical studies; 3. Active collaboration with academic, medical and industrial institutions in Boston area, around the US, and abroad. Current collaborations include – to name just a few - Massachusetts General Hospital, Beth Israel Hospital, Auburn University, University of Padova, Russian Oncology Center. The Center is funded by several NIH and industrial grants.